NIH Update Following ACD Recommendations on Enhancing Rigor, Transparency, and Translatability in Animal Research

Michael S. Lauer, MD
NIH Deputy Director for Extramural Research

NIH Advisory Committee to the Director (ACD) Meeting (Virtual)

June 9, 2022



ACD Enhancing Rigor, Transparency, and Translatability in Animal Research Working Group Members

External Members

Barbara Wold, PhD (Co-Chair)

Bren Professor of Molecular Biology Merkin Institute for Translational Research California Institute of Technology

Nancy Ator, PhD

Professor of Behavioral Biology Johns Hopkins School of Medicine

Lais Berro, PhD

Postdoctoral Fellow University of Mississippi Medical Center

Eliza Bliss-Moreau, PhD

Associate Professor; Core Scientist University of California, Davis

Romer A. Gonzalez Villalobos, MD, PhD, FAHA

Senior Principal Scientist
Janssen Research and Development, LLC

F. Claire Hankenson, DVM, MS, DACLAM

Attending Veterinarian; Director, Campus Animal Resources; Professor Michigan State University

Veronique Kiermer, PhD

Publisher & Executive Editor PLOS

Keisa W. Mathis, PhD

Assistant Professor University of North Texas Health Science Center

Sarah Nusser, PhD

Professor of Statistics Iowa State University

Sarah Nusser, PhD

Professor of Statistics Iowa State University

Regina Nuzzo, PhD

Senior Advisor for Statistics American Statistical Association

Eric Prager, PhD

Associate Director, External Affairs Cohen Veterans Bioscience

F. Daniel Ramirez, MD, MSc

Cardiac Electrophysiology Fellow University of Ottawa Heart Institute CHU Bordeaux, IHU Liryc

Karen Svenson, PhD

Senior Scientific Program Manager and Research Scientist Jackson Laboratory

ACD Enhancing Rigor, Transparency, and Translatability in Animal Research Working Group Members

USG MEMBERS

Lawrence A. Tabak, DDS, PhD (Co-Chair)

Principal Deputy Director, NIH

Brian Berridge, DVM, PhD, DACVP

Associate Director, National Toxicology Program; Scientific Director Division National Toxicology Program National Institute of Environmental Health Science, NIH

Paul Brown, PhD

Associate Director for Pharmacology and Toxicology Office of New Drugs, Center for Drug Evaluation and Research, FDA

Janine Clayton, MD

Director
Office of Research on Women's Health, NIH

Joshua A. Gordon, MD, PhD

Director National Institute of Mental Health, NIH

Michael Lauer, MD

Deputy Director for Extramural Research Office of Extramural Research, NIH

Robyn Lee-Stubbs, MS, CPIA, PStat®

IACUC Chair/Statistician
United States Army Medical Research Institute of Chemical Defense

Glenn Merlino, PhD

Scientific Director for Basic Research Center for Cancer Research, National Cancer Institute, NIH

Shai Silberberg, PhD

Director for Research Quality
National Institute of Neurological Disorders and Stroke, NIH

Carrie Wolinetz, PhD

Acting Chief of Staff; Associate Director Office of Science Policy, NIH

Recommendations: Five Themes

1. Improve Study Design and Analytic Rigor

2. Address Bias,
Incomplete Reporting and
Questionable Research
Practices

5. Measure and Evaluate Effectiveness and Costs

- 3. Improve Relevance and Use of Animal Models
- 4. Improve Methodologic and Results Reporting

Overview

- EAWG detailed review of recommendations
- DPCPSI ORIP NOSI and concept clearance on rigor, reproducibility, and translatability of animal research
- Planned workshops
- Existing resources and opportunities to better leverage them
- Ongoing efforts to enhance rigor and peer review
- Shorter-term considerations for discussion

EAWG = Extramural Activities Working Group

DPCPSI ORIP = Division of Program Coordination, Planning, and Strategic Initiatives

NOSI = Notice of Special Interest

Notice of Special Interest (NOSI): Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical

Research

Notice Number:

NOT-OD-22-039

Key Dates

Release Date:	December 7, 2021
First Available Due Date:	February 16, 2022
Expiration Date:	May 08, 2024

Related Announcements

PAR-21-167 - Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)

Issued by

Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)

ORIP NOSI Goals

- Exploratory/developmental and highly innovative projects aimed at developing broadly applicable technologies, tools, and resources for validating animal models and enhancing the rigor, reproducibility, and translatability of animal research
- [Proposals] ... must either address research interests of multiple NIH ICs, explore multiple body or organ systems, or be applicable to diseases and processes that impact multiple body or organ systems.


Concept Clearance

- DPCPSI ORIP presented to Council of Councils on May 19, 2022
- Grant mechanisms
 - 2-year R21
 - 5-year R01
 - 4-year R24 and U24
 - Small business
- Proposed projects must demonstrate how proposed resources and technologies will impact rigor and reproducibility of animal studies

Other Planned Workshops

- ORIP: animal models and related resources for COVID research
 - Leverages NIH-wide portfolio analysis
- ORIP: enhance rigor and reproducibility by managing extrinsic factors
 - Assess equipment, instrumentation, and extramural construction projects
- National Academies Institute for Laboratory Animal Research (ILAR)
 project on effective communication with the general public about
 scientific research that requires work with animals

Existing Resources



Statistical Topics for Reproducible Animal Research

Andrew W. Brown and David B. Allison, Indiana University School of Public Health-Bloomington; Tapan Mehta and Stephen Watts, University of Alabama at Birmingham, R25 GM116167

Preclinical research involving animal models can be improved when appropriate experimental, analytical, and reporting practices are used. We produced a series of animated vignettes with quantitative experts and laboratory scientists discussing aspects of study design, interpretation,



Controls in Animal Studies for Rigor and Reproducibility
Christina N. Bennett and Marsha Lakes Matyas, American Physiological Society,
R25 GM116166

This teaching module was designed to help biomedical researchers understand the changing standards of practice for studies using animals as research models. This module is comprised of three sections that focus on developing strong skills in designing animal studies, analyzing results from those studies, and reporting findings that are reproducible. Modules are designed to be used by higher education institutions, laboratory groups, individuals, and professional societies.

Highlighting Other Resources



Resources for Preparing Your Application

Learn how to prepare a rigorous application with select excerpts of rigor from awarded applications, authentication plan examples, and resources like the experimental design assistant (EDA), guidance on sample size calculation, and more.



The Experimental Design Assistant - EDA

Contents

- Overview
- Publications

Overview







Training and Other Resources

Resources and training on many aspects of rigor and reproducibility, including sex as a biological variable, research methods, reviewer guidance and more.

https://grants.nih.gov/policy/reproducibility/index.htm https://www.nc3rs.org.uk/our-portfolio/experimental-design-assistant-eda



View Reporting for Experiment Design



Preclinical validation of a potent γ-secretase modulator for Alzheimer's disease prevention

BIBLIOGRAPHIC THERAPEUTIC AGENT ANIMAL MODEL

EXPERIMENTAL DESIGN OUTCOMES

Bibliographic

Year of Publication: 2021

Experimental Design

Is the following information reported in the study?:

- ✗ Power/Sample Size Calculation
- Blinded for Treatment
- Pharmacokinetic Measures
- Toxicology Measures
- Biomarkers
- ✓ Formulation
- ✓ Duration of Treatment
- Age of Animal at the Beginning of Treatment
- Sex as a Biological Variable
- X Number of Premature Deaths
- Statistical Plan
- X Inclusion/Exclusion Criteria Included

- Randomized into Groups
- Blinded for Outcome Measures
- ✓ Pharmacodynamic Measures
- ADME Measures
- Dose
- Route of Delivery
- Frequency of Administration
- ✓ Age of Animal at the End of Treatment
- Study Balanced for Sex as a Biological Variable
- X Number of Excluded Animals
- Genetic Background
- Conflict of Interest

Ongoing Rigor Efforts

- CSR Advisory Council Workgroup on Simplifying Review Criteria
 - Focus on what's important: five to three criteria
 - Should it be done? → Importance of the science
 - Can it be done well? → Feasibility and rigor
 - Will it be done? → Investigators and environment
 - Further ACD discussion later this year
- NIH Data Management and Sharing Policy (later this ACD)

NINDS Activities

Funding Opportunity Title	Creating an Educational Nexus for Training in Experimental Rigor (CENTER) (UC2 Clinical Trial Not Allowed)
Funding Opportunity Title	Materials to Enhance Training in Experimental Rigor (METER) (UE5 Clinical Trial Not Allowed)

[These] Funding Opportunity Announcements (FOAs) ... together aim to facilitate teaching of fundamental principles of rigorous biomedical research by developing an innovative online educational resource for use by a broad range of researchers in an array of learning environments.


Catalyzing Communities of Research Rigor Champions

A Workshop Hosted by the NINDS Office of Research Quality

May 23-24, 2022 NIH Campus, Bethesda, MD

https://www.infinityconferences.org/ResearchRigorChampions

Co-Chairs:



Steven Goodman, Stanford University



Veronique Kiermer, PLOS

Possible Short to Intermediate Efforts

- Guide Notice to encourage use of ARRIVE Guidelines when reporting results of NIH-funded animal research
 - Many journals already encourage or require ARRIVE
- Fund statistical cores to support animal researchers at underresourced institutions
- Non-monetary prize to highlight exemplary work in study design and analysis in animal research